NantHealth Inc (NASDAQ:NH) was the recipient of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 170,600 shares, a decline of 23.9% from the January 15th total of 224,300 shares. Based on an average daily volume of 236,700 shares, the short-interest ratio is presently 0.7 days. Currently, 0.5% of the company’s shares are short sold.

Shares of NASDAQ:NH traded down $0.06 during trading hours on Friday, hitting $1.68. The company’s stock had a trading volume of 258,700 shares, compared to its average volume of 1,141,613. NantHealth has a 52 week low of $0.45 and a 52 week high of $2.75. The company has a market capitalization of $189.16 million, a price-to-earnings ratio of -1.85 and a beta of 1.32. The firm’s fifty day moving average price is $1.40 and its 200 day moving average price is $0.92.

Several large investors have recently bought and sold shares of NH. Paragon Wealth Strategies LLC bought a new position in shares of NantHealth during the 4th quarter worth approximately $38,000. Tower Research Capital LLC TRC raised its stake in shares of NantHealth by 778.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 45,988 shares of the company’s stock worth $33,000 after acquiring an additional 40,755 shares in the last quarter. Bank of America Corp DE bought a new position in shares of NantHealth during the 4th quarter worth approximately $31,000. Renaissance Technologies LLC raised its stake in shares of NantHealth by 28.1% during the 4th quarter. Renaissance Technologies LLC now owns 513,728 shares of the company’s stock worth $529,000 after acquiring an additional 112,605 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of NantHealth by 74.4% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 88,640 shares of the company’s stock worth $91,000 after acquiring an additional 37,812 shares in the last quarter. Institutional investors and hedge funds own 2.84% of the company’s stock.

A number of equities analysts recently commented on the stock. Zacks Investment Research cut shares of NantHealth from a “buy” rating to a “hold” rating in a research note on Thursday, December 19th. ValuEngine raised shares of NantHealth from a “sell” rating to a “hold” rating in a research note on Tuesday, February 4th.

About NantHealth

NantHealth, Inc, together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.

Featured Article: How To Calculate Debt-to-Equity Ratio

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.